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Conclusion: Our study demonstrates that the pelvic lymph 
nodes receive a significant dose contribution from 
brachytherapy in cervical cancer, when employing the 
Manchester prescription system. This must be taken into 
account during external beam radiotherapy planning, and 
adequate external beam boost doses calculated to achieve 
cumulative tumoricidal doses to pelvic nodal disease.  
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Purpose or Objective: Endometrial cancer is the mainly 
gynaecologic malignancy, 80-85% in stage I at diagnosis. The 
standard primary treatment remains TAH&BSO, with 
appropriate surgical staging. The epidemiology of this disease 
favours elderly, obese women with multiple medical 
problems (hypertension, diabetes, cardiovascular diseases, 
coagulation disorders, respiratory disorders) that render 
some of them medically inoperable. RT alone is the only 
efficient option for these women. BT is the main component 
in this cohort of patients (pts). 
 
Material and Methods: September 1997-September 2015: 90 
pts RT alone, 71 BT HDR alone. Median age 79 years (range 
57-93). Staging: clinical examination, TVUS, MR or CT scan 
and fractionated curettage. Stage Ia 32 pts, Stage Ib 36 pts, 
Stage II 3 pts. OS, DSS, LC and late side effects were analysed 
retrospectively. Follow-up > 10 years (mean 57 months). BT 
HDR with Rotte “Y” applicator, plus VBT in stage II. Dose 
prescription at ‘‘uterine points’’ that are two points located 
1 cm over the middle of a line drawn between the tips of the 
two ends of the "Y" applicator and at series of points placed 
laterally to the tandem according to the pre-treatment 
imaging data. We treat the entire length of the uterus to 
ensure coverage of the fund. To maintain the bladder and 
rectal maximum point doses below 100% of the prescribed 
dose we optimize with TPS. Until 2002 BT was performed 4-5 
times, weekly, mean dose 29.3 Gy (range 18-35 Gy); from 
2003 (42 pts) we deliver 30 Gy in five frs, 6 Gy each b.i.d. 
schedule, 6 hours interval between frs. 
 
Results: 5 years OS, DSS and LC: 52.1%, 85.9%, and 91.2%. 
Stage Ia: 56.3%, 87.5%, and 90.6%; Stage Ib: 50%, 86.1%, 
and 94.4%; Stage II: 33.3%, 66.7%, and 66.7%. DSS was not 
affected by tumour grade or age. One patient had a PD, 6 
(10.6%) developed recurrence after a median of 13 months (3 
with distant metastases), 2 (3.5%) a lymph node recurrence 
with distant metastases. One patient have a GE grade III late 
side effect (1.8%) at 5 years, not related with rectal dose. 
 
Conclusion: HDR BT with “Y” applicator is a very effective 
treatment modality with good LC rates and suitable DSS for 
pts who are not fit for surgery. This technique has proven to 
have a low risk of acute complications and long-term side 
effects. Longer follow-up will be required to document the 
incidence of late effects using the b.i.d. schedule. In the 
short term, it seems that this approach is a feasible way to 
limit the number of procedural complications and length of 
hospital stay and bed rest. 
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Purpose or Objective: Basal cell carcinoma (BCC) is a very 
common cancer in the Caucasian population. Treatment aims 
to eradicate the tumor with the lowest possible functional 
and aesthetic impact. Electronic brachytherapy (EBT) is a 
treatment technique currently emerging. This study aims to 
show the outcomes of two consecutive prospective pilot 
clinical trials using different radiation doses of EBT with 
Esteya® EB system for the treatment of superficial and 
nodular basal cell carcinoma. 
 
Material and Methods: Two prospective, single-center, non-
randomized, pilot studies were conducted. Twenty patients 
were treated in each study with different doses. The first 
group (1) was treated with 36.6 Gy in 6 fractions of 6.1 Gy 
and the second group (2) with 42 Gy in 6 fractions of 7 Gy. In 
one case the 6.1 Gy/fraction resulting from the theorical RBE 
calculation was used, and in the second arm (7 Gy/fraction) 
the same dose as the Valencia applicator study was used. 
Cure rate, acute toxicity and late toxicity related to cosmesis 
were analyzed in the two treatment groups.  
 
Results: In group 1, a complete response in 90% of cases was 
observed at the 1 year follow-up, whereas in group 2 the 
complete response was 95%. Tumor persistence or recurrence 
was suspected clinically and dermoscopically in two patients 
in the first group at 3 and 6 months respectively and in one 
patient in the second group at 1 year follow-up. The 
differences with reference to acute toxicity and the cosmetic 
results between the two treatment groups were not 
statistically significant.  
 
Conclusion: Our initial experience with Esteya® EB system to 
treat superficial and nodular BCC shows that a dose of 36.6 
Gy and 42 Gy delivered in 6 fraction of 7 Gy achieves a 90% 
and 95% clinical cure rate at 1 year respectively. Both groups 
had a tolerable toxicity and a very good cosmesis. 
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Purpose or Objective: Feasibility and dosimetric study of 3D-
printed cylindrical and skin mould applicators for High Dose 
Rate brachytherapy (HDR-BRT) using acrylonitrile butadiene 
styrene (ABS). 
 
Material and Methods: Three cylindrical applicators (1 as 
reference and 2 as test) with a single 2.5 mm catheter 
channel and a 1 mm radial slit for radiochromic film support 
were 3D printed (HP3DX100, Hamlet, Dublin, IE) using ABS 
plastic. The reference had the radiochromic slit in contact 
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with the catheter channel and was printed with 20% infill 
percentage. The test configurations had the radiochromic slit 
at 6.3 mm distance from the center of the catheter channel 
and were printed with 20% (Test 1) and 40% (Test 2) infill 
percentage. Physical quality of ABS plastic were evaluated by 
analyzing the depth dose profiles measured by Gafchromic 
EBT3 films (International Specialty Products, Wayne, NJ) 
when the 192Ir source passing through the catheter channel 
delivered 2 Gy at 10 mm distance from the axis of the 
channel (Fig.1a).  
Four skin mould applicators with 4 parallel catheter channels 
of 2.5 mm diameters, 5 mm distance between the axis of the 
channel and the surface, and 10 mm distance between 
consecutive channel axes were 3D-printed. Two geometrical 
shapes were compared to the commercial Freiburg Flap 
applicator (Nucletron, Stockholm, SE, Fig. 1b): a group of 16 
semi-spheres reproducing the actual Freiburg geometry 
printed at 10% infill percentage (Fig.1c) and a parallelepiped 
applicator with 10%, 20% and 40% infill printing percentage 
(Fig.1d). A prescription dose of 2 Gy to the surface at 5 mm 
distance from the channels axes was delivered using an 192Ir 
source. Surface dose distributions were measured with 
Gafchromic EBT3 films for both the 3D-printed skin mould 
applicators and the commercial Freiburg Flap applicator 
considered as reference. The gamma index method with dose 
difference (DD) criteria of 3%, distance-to-agreement criteria 
(DTA) of 3 mm and 10% dose threshold was evaluated. 
 
 
 
Results: The radiation attenuation profiles were comparable 
in all the cylindrical configurations. Dose attenuation were 
not sensitive to the density of the material (Tab.1a). When 
comparing 3D-printed skin mould applicators with 
commercial Freiburg Flap in terms of gamma index analysis, a 
high pass rates >90% was obtained. Therefore, the isodose 
overlay and linear dose profiles of film measured using 3D 
printed applicator and commercial Freiburg were in close 
agreement (Tab.1b). 
 
 
Conclusion: ABS3D-printed applicators are a reliable solution 
for patient-specific HDR-BRT of superficial lesions. Further 
assessment of 3D printing techniques and materials are 
required for clinical development.  
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Purpose or Objective: Local residual disease occurs in 7-13 % 
after primary treatment for nasopharyngeal carcinoma (NPC). 
To prevent tumor progression and/or distant metastasis, 
treatment is indicated. This studies focus on the application 
of 3D-CT based and endoscopical guided brachytherapy for 
the treatment of residual lesion in nasopharyngeal cavity of 
NPC after the radical external beam radiotherapy and to 
assess the safety and clinical outcome of this technical. 
 
Material and Methods: 26 patients with stage T1-T2b NPC 
who suffered from locally residual lesion in nasopharyngeal 
cavity (All the tumors were less than 1 cm below the 
nasopharyngeal epithelium) after standard radical 
radiotherapy (70-74 Gy) ± platinum-based chemotherapy 
were further administrated by the 3D-CT based and 
endoscopical guided brachytherapy using the Foshan 
applicator or the standard nasopharyngeal applicator 
according the tumor location. The prescribed salvage dose of 
brachytherapy was 3.5 Gy/fraction, twice- daily with an 
interval of 6 h to a total dose of 7-14 Gy (one week apart) 
depending on the total dose of external beam radiotherapy. 
The total dose ranged from 81.8-85.6 Gy when transformed 
to EQD2 models, and the Pstem D1%< 60 Gy was restricted in 
planning. The primary endpoint was 1-, 3-year overall 
survival and secondary endpoints were: local control, distant 
metastasis and grade 3-4 adverse events. 
 
Results: The whole brachytherapy procedure was well 
tolerated under local anesthesia. 24 patients (92.3%) get 
complete response (CR) as confirmed by enhanced CT/MRI 
after 1-3 month after the brachytherapy. With a median 
follow-up time of 40 months, no serious complications or late 
sequelae occurred. The 1-, and 3-year overall survival, 
locoregional free survival, and distant-metastasis free 
survival rates were 96.2%, 80.8%, 92.3% and 84.6%, 
respectively. And the patients with early-T stage at initial 
diagnosis had 100% local control rate. 
 
Conclusion: Brachytherapy is of benefit to improve the local 
control of primary lesion of NPC with residual nasopharyngeal 
cavity involvement. It is a safe and effective approach for 
patients with poor tumor regression at the end of external 
beam radiotherapy for boosting the local irradiation dose.  
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Purpose or Objective: Total salvage Iodine-125 
brachytherapy (TS I-125-BT) is a potentially curative 
treatment strategy for localized prostate cancer (PCa) 
recurrences after radiotherapy. Prognostic factors influencing 
PCa-specific and overall mortality (PCaSM & OM) are not 
known. The objective was therefore to develop a 
multivariable, internally validated prognostic model for 
survival after TS I-125-BT. 
 
Material and Methods: Retrospectively, sixty-two TS I-125-BT 
patients were analyzed. These patients were treated from 
1993-2010 in the Netherlands. Multivariable Cox-regression 
was used to assess the influence of pre-salvage 
characteristics on PCaSM and OM. Missing data was handled 
by using multiple imputation (20 imputed sets). Internal 
validation was done using 500 bootstrap resamples of every 
imputed set. Discriminatory ability was quantified with the C-
statistic. Calibration plots were created to visually assess the 
